Last updated: February 17, 2026
What is NDC 24208-0358?
NDC 24208-0358 is a prescription drug product identified as Sabal (sabal extract), which is used for therapeutic purposes related to prostate health, specifically benign prostatic hyperplasia (BPH). The drug is marketed primarily in the herbal supplement and alternative medicine markets but also has formulations that may fall under prescription drug coverage.
Market Overview
Market size: The global BPH treatment market was valued at approximately $5.2 billion in 2022, with herbal and natural supplement segments making up roughly 12% of that total, estimated at around $624 million.
Key competitors: Finasteride (Proscar, Propecia), Dutasteride (Avodart), and herbal treatments such as saw palmetto extracts, including Sabal extract. These have established markets with high brand loyalty and established prescriptions.
Regulatory status: Sabal extract variants are commercially available as dietary supplements in the United States under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Prescription formulations are less common, limiting direct prescription-based revenue streams.
Market dynamics
-
Consumer demand: Growing interest in natural and herbal remedies for BPH. However, efficacy evidence remains mixed.
-
Regulatory landscape: Surface-level herbal extracts like Sabal are unregulated as drugs but monitored as dietary supplements. Transitioning to prescription drug status requires clinical trials, data, and FDA approval.
-
Reimbursement environment: Supplements are typically paid out-of-pocket; prescription versions might qualify for insurance but are limited in availability.
Price projections
Current pricing landscape
| Product Type |
Average Price Range (USD) |
Notes |
| Dietary supplements (Sabal) |
$15 - $35 per bottle |
Typically 60-120 capsules |
| Prescription Sabal extract |
Not widely available |
Estimated to cost $150 - $300 per month |
Future price trajectory assumptions
| Scenario |
Rationale |
Price Range (USD) |
| Baseline |
No new approvals, current market trends |
$15 - $35 (supplement) |
| Moderate Growth |
Entry of FDA-approved prescription versions |
$150 - $250 per month |
| Aggressive Innovation |
Novel formulations with superior bioavailability |
$250 - $350 per month |
Drivers affecting prices
-
Regulatory approval: FDA approval of Sabal as a prescription drug could significantly increase the price due to clinical trial costs and branded positioning.
-
Market penetration: Rise in demand for herbal therapies can push supplement prices upward, especially if new clinical data supports efficacy.
-
Manufacturing costs: Higher purity or standardized extracts could increase production costs, impacting retail prices.
Key considerations
-
If Sabal gains FDA approval and is marketed as a prescription medication, pricing could align with current BPH drugs, which range from $150 to $300 per month.
-
The herbal supplement market maintains lower prices due to minimal regulation, high competition, and consumer price sensitivity.
-
Competitive pricing would likely be constrained by existing efficacious therapies; thus, a premium price would depend on demonstrated superior efficacy.
Caveats and uncertainties
- Lack of recent large-scale clinical trials could delay or prevent FDA approval.
- Market acceptance hinges on clinical evidence, marketing, and physician adoption.
- Pricing strategies depend on regulatory outcomes and competitive responses.
Key Takeaways
- NDC 24208-0358, as Sabal extract, exists mainly in the dietary supplement space with prices around $15-35.
- FDA approval could elevate the product to prescription status, with expected monthly costs of $150-$300.
- Market growth depends on scientific validation, regulatory developments, and consumer trends toward herbal remedies.
- Competitive pressures from established pharmaceuticals limit premium pricing unless superior efficacy is demonstrated.
- The herbal supplement market remains highly price-sensitive and is unlikely to sustain high prices without regulatory support.
FAQs
Q1: What are the main barriers to FDA approval for Sabal?
Clinical trial data demonstrating safety and efficacy in treating BPH are required. Current evidence from small studies is insufficient for approval.
Q2: How does herbal supplement pricing compare globally?
Prices vary widely; in the US, typical supplements range from $10 to $30 per bottle, with some premium products exceeding $50.
Q3: How might regulatory changes impact the herbal supplement market?
Increased FDA scrutiny could lead to tighter control and potential reclassification, possibly raising costs and reducing availability as supplements.
Q4: What is the typical reimbursement landscape for herbal vs. prescription Sabal?
Supplements are paid out-of-pocket; prescription versions might be reimbursed partially depending on healthcare coverage policies.
Q5: Will consumer preferences favor standard pharmaceuticals over herbal treatments?
Trend analysis shows rising interest in herbal remedies, but efficacy concerns and healthcare provider recommendations influence acceptance of pharmaceutical options.
Sources:
[1] MarketsandMarkets, “Benign Prostatic Hyperplasia Treatment Market,” 2023.
[2] FDA, “Dietary Supplements,” 2022.
[3] IQVIA, “Pharmaceutical Market Reports,” 2023.
